- Home
- HRMY vs CMPR Comparison
HRMY vs CMPR Comparison
Compare HRMY & CMPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HRMY
- CMPR
- Stock Information
- Founded
- HRMY 2017
- CMPR 1994
- Country
- HRMY United States
- CMPR Ireland
- Employees
- HRMY N/A
- CMPR N/A
- Industry
- HRMY Biotechnology: Pharmaceutical Preparations
- CMPR Publishing
- Sector
- HRMY Health Care
- CMPR Consumer Discretionary
- Exchange
- HRMY Nasdaq
- CMPR Nasdaq
- Market Cap
- HRMY 1.8B
- CMPR 1.1B
- IPO Year
- HRMY 2020
- CMPR N/A
- Fundamental
- Price
- HRMY $34.00
- CMPR $48.07
- Analyst Decision
- HRMY Strong Buy
- CMPR Strong Buy
- Analyst Count
- HRMY 9
- CMPR 2
- Target Price
- HRMY $54.44
- CMPR $62.50
- AVG Volume (30 Days)
- HRMY 642.5K
- CMPR 324.3K
- Earning Date
- HRMY 08-05-2025
- CMPR 07-30-2025
- Dividend Yield
- HRMY N/A
- CMPR N/A
- EPS Growth
- HRMY 13.13
- CMPR 83.61
- EPS
- HRMY 2.62
- CMPR 5.97
- Revenue
- HRMY $744,852,000.00
- CMPR $3,366,207,000.00
- Revenue This Year
- HRMY $20.10
- CMPR $4.65
- Revenue Next Year
- HRMY $18.01
- CMPR $3.16
- P/E Ratio
- HRMY $13.10
- CMPR $8.11
- Revenue Growth
- HRMY 20.62
- CMPR 3.64
- 52 Week Low
- HRMY $26.47
- CMPR $35.21
- 52 Week High
- HRMY $41.61
- CMPR $104.92
- Technical
- Relative Strength Index (RSI)
- HRMY 58.91
- CMPR 56.48
- Support Level
- HRMY $31.70
- CMPR $45.73
- Resistance Level
- HRMY $35.08
- CMPR $50.48
- Average True Range (ATR)
- HRMY 0.95
- CMPR 1.97
- MACD
- HRMY 0.27
- CMPR 0.14
- Stochastic Oscillator
- HRMY 71.80
- CMPR 69.47
About HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
About CMPR Cimpress plc (Ireland)
Cimpress PLC invests in and builds customer-focused, entrepreneurial, mass-customization businesses for the long term. Mass customization seeks to produce goods and services to meet individual customer needs with near mass production efficiency. Its products and services include a broad range of marketing materials, business cards, signage, promotional products, logo apparel, packaging, books and magazines, wall decor, photo merchandise, invitations and announcements, design and digital marketing services, and other categories. The company's segment includes Vista; PrintBrothers; The Print Group; National Pen and All Other Businesses. It generates maximum revenue from the Vista segment.